Safaa Mohammed Elmahdy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Safaa Mohammed Elmahdy has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Amany Mohamed Hamed
Chemistry Department, Faculty of Science, Sohag University, Sohag 82524, Egypt
2 shared publications - Elsayed Eldeeb Mehana Hamouda
Department of Pathology, College of Veterinary Medicine, Alexandria University, Alexandria 26571, Egypt
2 shared publications - Rasha Abdeen Refaei
Department of Physiology, Faculty of Medicine, Sohag University, Sohag 82524, Egypt
2 shared publications - Safaa S. Soliman
Department of Zoology, Faculty of Science, Minia University, Minia 61519, Egypt
2 shared publications - Aboubakr H. Abdelmonsef
Chemistry Department, Faculty of Science, Qena University, Qena 83523, Egypt
1 shared publication - Ahmed M. Refaat
Zoology Department, Faculty of Science, Minia University, El-Minia, 61519, Egypt.
1 shared publication
Latest Publications
- Open Access
- 14 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8184
Aucubin Ameliorates Alloxan-Induced Diabetic Liver Injury in Association with Modulation of the Nrf2/HO-1 Antioxidant Axis and NF-κB-Associated Inflammatory and Apoptotic Signaling
Diabetes mellitus is associated with progressive hepatic injury driven by oxidative stress, inflammation, and apoptosis. Aucubin, a natural iridoid glycoside, possesses potent antioxidant and anti-inflammatory activities; however, its hepatoprotective mechanisms in diabetic liver injury remain unclear. This study investigated the protective effects of aucubin against alloxan-induced diabetic hepatic injury and the underlying molecular mechanisms. Male albino rats were assigned to five groups: normal control, alloxan-induced diabetic, diabetic treated with metformin (150 mg/kg), and diabetic treated with aucubin (25 or 50 mg/kg) for 28 days. We evaluated body weight, fasting blood glucose, liver function, lipid profile, oxidative stress biomarkers, inflammatory cytokines, and hepatic expression of Nrf2, HO-1, NF-κB p65, Bax, and Bcl-2, along with histopathological and immunohistochemical examinations. Alloxan induced marked hyperglycemia, weight loss, hepatic dysfunction, dyslipidemia, oxidative stress, inflammation, and apoptosis. Aucubin significantly ameliorated these alterations, with the 50 mg/kg dose generally showing greater effects than the 25 mg/kg dose. Aucubin improved liver function, ameliorated dyslipidemia, reduced lipid peroxidation, enhanced antioxidant defenses, increased Nrf2 and HO-1 expression, attenuated NF-κB p65 expression and pro-inflammatory cytokines, favorably modulated the Bax/Bcl-2 balance, preserved hepatic architecture, and increased Ki-67 immunoreactivity, indicating enhanced cellular proliferative activity. These findings indicate that aucubin is associated with improved hepatic antioxidant, inflammatory, apoptotic, and metabolic status in alloxan-induced diabetic rats.
- 14 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8184
Open AccessAucubin Ameliorates Alloxan-Induced Diabetic Liver Injury in Association with Modulation of the Nrf2/HO-1 Antioxidant Axis and NF-κB-Associated Inflammatory and Apoptotic Signaling
Diabetes mellitus is associated with progressive hepatic injury driven by oxidative stress, inflammation, and apoptosis. Aucubin, a natural iridoid glycoside, possesses potent antioxidant and anti-inflammatory activities; however, its hepatoprotective mechanisms in diabetic liver injury remain unclear. This study investigated the protective effects of aucubin against alloxan-induced diabetic hepatic injury and the underlying molecular mechanisms. Male albino rats were assigned to five groups: normal control, alloxan-induced diabetic, diabetic treated with metformin (150 mg/kg), and diabetic treated with aucubin (25 or 50 mg/kg) for 28 days. We evaluated body weight, fasting blood glucose, liver function, lipid profile, oxidative stress biomarkers, inflammatory cytokines, and hepatic expression of Nrf2, HO-1, NF-κB p65, Bax, and Bcl-2, along with histopathological and immunohistochemical examinations. Alloxan induced marked hyperglycemia, weight loss, hepatic dysfunction, dyslipidemia, oxidative stress, inflammation, and apoptosis. Aucubin significantly ameliorated these alterations, with the 50 mg/kg dose generally showing greater effects than the 25 mg/kg dose. Aucubin improved liver function, ameliorated dyslipidemia, reduced lipid peroxidation, enhanced antioxidant defenses, increased Nrf2 and HO-1 expression, attenuated NF-κB p65 expression and pro-inflammatory cytokines, favorably modulated the Bax/Bcl-2 balance, preserved hepatic architecture, and increased Ki-67 immunoreactivity, indicating enhanced cellular proliferative activity. These findings indicate that aucubin is associated with improved hepatic antioxidant, inflammatory, apoptotic, and metabolic status in alloxan-induced diabetic rats.
- Open Access
- 1 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (9) , 4072
Chitosan-Based Taurine Nanoparticles Alleviate Dexamethasone-Induced Pulmonary–Thyroid Axis Dysfunction via Redox–Inflammatory Signaling Modulation in Rats
Dexamethasone induces systemic toxicity, including oxidative stress, inflammation, hematological disturbances, and organ damage, particularly in the lungs and thyroid. Taurine exhibits antioxidant and anti-inflammatory properties, but poor bioavailability limits its efficacy. Nanoparticle delivery may enhance stability and tissue targeting. This study aimed to evaluate the protective effects of taurine-loaded chitosan nanoparticles (Tau–CS NPs) against dexamethasone-induced tissue injury in rats. Forty-eight male Wistar rats were allocated into control, DEXA, DEXA + silymarin, DEXA + taurine, and DEXA + Tau–CS NPs groups. Tau–CS NPs were characterized by TEM, UV–vis, FTIR, encapsulation efficiency, and drug loading. Hematology, oxidative stress markers (CAT, SOD, GSH, MDA), thyroid hormones (T3, T4, TSH, calcitonin), protein profile, lung and thyroid histopathology, and MPO expression were assessed. Tau–CS NPs showed uniform spherical morphology (11–60 nm), high encapsulation (98.2%), and substantial loading (50.36%). Dexamethasone caused hematological, oxidative, thyroidal, and histological disturbances. Tau–CS NPs markedly restored hematological indices, antioxidant defenses, thyroid function, protein profile, and tissue architecture, outperforming free taurine and silymarin. MPO expression was significantly reduced, indicating decreased inflammation. Taurine nanoparticles effectively mitigate dexamethasone-induced systemic and organ-specific toxicity, offering improved bioavailability and targeted delivery, highlighting their therapeutic potential.
- 1 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (9) , 4072
Open AccessChitosan-Based Taurine Nanoparticles Alleviate Dexamethasone-Induced Pulmonary–Thyroid Axis Dysfunction via Redox–Inflammatory Signaling Modulation in Rats
Dexamethasone induces systemic toxicity, including oxidative stress, inflammation, hematological disturbances, and organ damage, particularly in the lungs and thyroid. Taurine exhibits antioxidant and anti-inflammatory properties, but poor bioavailability limits its efficacy. Nanoparticle delivery may enhance stability and tissue targeting. This study aimed to evaluate the protective effects of taurine-loaded chitosan nanoparticles (Tau–CS NPs) against dexamethasone-induced tissue injury in rats. Forty-eight male Wistar rats were allocated into control, DEXA, DEXA + silymarin, DEXA + taurine, and DEXA + Tau–CS NPs groups. Tau–CS NPs were characterized by TEM, UV–vis, FTIR, encapsulation efficiency, and drug loading. Hematology, oxidative stress markers (CAT, SOD, GSH, MDA), thyroid hormones (T3, T4, TSH, calcitonin), protein profile, lung and thyroid histopathology, and MPO expression were assessed. Tau–CS NPs showed uniform spherical morphology (11–60 nm), high encapsulation (98.2%), and substantial loading (50.36%). Dexamethasone caused hematological, oxidative, thyroidal, and histological disturbances. Tau–CS NPs markedly restored hematological indices, antioxidant defenses, thyroid function, protein profile, and tissue architecture, outperforming free taurine and silymarin. MPO expression was significantly reduced, indicating decreased inflammation. Taurine nanoparticles effectively mitigate dexamethasone-induced systemic and organ-specific toxicity, offering improved bioavailability and targeted delivery, highlighting their therapeutic potential.